TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.43.

Several equities research analysts have recently issued reports on TGTX shares. TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday. They issued a "buy" rating and a $50.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its holdings in TG Therapeutics by 3.9% during the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock worth $538,000 after buying an additional 1,322 shares during the period. Swiss National Bank raised its holdings in TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company's stock worth $4,321,000 after purchasing an additional 1,500 shares in the last quarter. Quantum Private Wealth LLC lifted its position in shares of TG Therapeutics by 13.7% during the first quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company's stock valued at $1,576,000 after buying an additional 12,523 shares during the last quarter. Sei Investments Co. purchased a new position in shares of TG Therapeutics in the 1st quarter worth approximately $591,000. Finally, Russell Investments Group Ltd. grew its position in shares of TG Therapeutics by 133.5% in the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company's stock worth $796,000 after buying an additional 29,923 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

Shares of TGTX stock traded down $0.07 on Thursday, reaching $25.06. The stock had a trading volume of 2,233,603 shares, compared to its average volume of 3,609,126. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. TG Therapeutics has a 1 year low of $7.17 and a 1 year high of $26.41. The stock has a market cap of $3.87 billion, a P/E ratio of 110.43 and a beta of 2.21. The company has a 50 day simple moving average of $23.44 and a 200 day simple moving average of $19.89.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same period in the previous year, the company posted ($0.34) EPS. The firm's revenue was up 357.0% on a year-over-year basis. Equities research analysts expect that TG Therapeutics will post 0.13 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.